MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), is pleased to announce its participation in the American Nurses Credentialing Center (“ANCC”) National Magnet Conference® from Wednesday, October 30 to Saturday, November 1, 2024, in New Orleans, LA.
The ANCC National Magnet Conference® is a premier event for nurses seeking to align with ANCC standards, build valuable connections with nursing leaders and peers, and explore the latest trends with global nursing experts. Covalon will be showcasing its innovative vascular access solutions at Booth 562, demonstrating how they can help support nurses in providing high-quality patient care.
“We’re excited to join the 2024 Magnet Conference and connect with nurses from across the country,” said Ron Hebert, Senior Vice President of Growth at Covalon. “Our gentle-to-skin silicone adhesive IV securement dressings and vascular access line guards reflect our belief that compassionate care starts with technology that can help protect every patient. This commitment aligns with the conference’s mission to provide nurses with tools and educational opportunities that drive nursing excellence. We look forward to sharing our latest innovations with attendees, as well as the opportunity to learn from the remarkable speakers and attendees at this event.”
At the Covalon booth, nurses can:
- Learn about the company’s latest vascular access products to help improve patient comfort.
- See live demonstrations of Covalon’s medical products.
- Network with Covalon representatives and other health care professionals.
Covalon’s patented vascular access products include:
- VALGuard®: Transparent vascular access line guard designed to protect IV line connections and hubs from external contaminants, including body fluids and other secretions.
- IV Clear®: Dual antimicrobial clear silicone adhesive IV securement dressing with chlorhexidine and silver that provides antimicrobial protection throughout the entire dressing surface area.
- CovaClear® IV: Clear soft silicone adhesive IV dressing that helps protect insertion sites from external contaminants. Suitable for patients who either don’t require, or cannot tolerate, antimicrobials.
- SurgiClear®: Dual antimicrobial clear silicone adhesive dressing with chlorhexidine and silver used to cover and protect wound sites and wound closure devices.
Scheduling Appointments and Additional Information
To book an appointment with a Covalon representative, please email Ron Hebert, SVP Growth, Covalon Technologies Ltd., at rhebert@covalon.com.
Conference Details
- Dates: October 30 – November 1, 2024
- Location: New Orleans Ernest N. Morial Convention Center, 900 Convention Center Blvd., New Orleans, Louisiana 70130
- Registration: https://magnetpathwaycon.nursingworld.org/conference-registration
For healthcare providers unable to attend the conference, Covalon encourages you to visit www.covalon.com or follow the company on LinkedIn, Facebook, or Instagram to learn more about its solutions.
About Covalon
Covalon is a patient-driven medical device company, that provides innovative and cost-effective healthcare solutions for advanced wound care, infection control, and medical device coatings. Through a strong portfolio of patented technologies and solutions, we offer innovative, gentle and more compassionate options to aid patients on their healing journey. Our solutions are designed for patients and made for care providers. Covalon leverages its patented medical technology platforms and expertise in two ways: (i) by developing products that are sold under Covalon’s name; and (ii) by developing and commercializing medical products for other medical companies under development and license contracts. The Company is listed on the TSX Venture Exchange, having the symbol COV and trades on the OTCQX Market under the symbol CVALF. To learn more about Covalon, visit our website at www.covalon.com.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend", or variations of such words and phrases or state that certain actions, events, or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur”, or “be achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management’s expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the “Risks and Uncertainties” section of our management’s discussion and analysis of financial condition and results of operations for the year ended September 30, 2023, which is available on the Company’s profile at www.sedarplus.ca, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law.
